Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports

Released April 1, 2022

Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.

Latest articles

Yuhong Dong In part 1 and part 2 of this series, we...
Yuhong Dong While the underlying mechanisms causing these autoimmune reactions are not...
Yuhong Dong The decline of public trust in COVID-19 vaccines significantly impacts...
Michael Passwater Vitamin D has important influences on many phases in the...
newmedicineonline.com When understanding the construct of an immune system we must begin...
Travis Noakes A major concern is that this agenda lacks earnest discussion...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!